Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Nov 19, 2021 1:55pm
353 Views
Post# 34146845

Stuff...

Stuff...Much of the recent buying is being done by long term shareholders. I think that the efforts to accurately inform shareholders, to whatever degree accuracy has been achieved, have helped shareholders retain confidence in Bioasis. This will show itself as the story unfolds when the usual broad selling on news turns out to be limited because shareholders retain high expectations for Bioasis.

I think this confidence is warranted.

Keep an eye on Johnson & Johnson. That company's spin off of its commercial products division and the reduced baby-powder legal liabilities that the remaining J&J may face could result in some interesting initiatives on J&J's and subsidiary Janssen's parts. In addition to long rumoured activities between Bioasis and the J&J companies, there were some interesting comments made by J&J at the Sachs & Associates Alzheimer's Progress conference that Bioasis attended in May. J&J's comments seemed tailormade for Bioasis's strategic plan.

The Bioasis information circular and other AGM documents have been available for a day or two on SEDAR. 

I wouldn't expect to see news coming out between the dates that AGM voting starts and the AGM. News at any point from now on would mean that early shareholders may be voting without the same information that later voters would have. There may be a regulation about that but I have never read it if it exists.

Happy voting, everybody. I recommend full support for the whole thing. I have never seen Bioasis in such good shape as it is right now. The market hasn't quite grasped that yet but it will if DrDR delivers as seems both apparent and imminent.

jd
<< Previous
Bullboard Posts
Next >>